Silver Book Fact

The overall five-year survival rate for men with prostate cancer is 99 percent—up from 43 percent in 1975.

Lichtenberg, Frank R. The Expanding Pharmaceutical Arsenal in the War on Cancer. National Bureau of Economic Research. February 2004; Working Paper No. 10328. http://www.nber.org/papers/w10328

Reference

Title
The Expanding Pharmaceutical Arsenal in the War on Cancer
Publication
National Bureau of Economic Research
Publication Date
February 2004
Authors
Lichtenberg, Frank R
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Use of a monocolonal antibody with adjuvant chemotherapy in HER2+ individuals with operable cancer was associated with a 33 percent reduction in risk of death.  
  • A drug that can reduce the risk of breast cancer in high-risk women costs approximately $1,050 per year. The average cost per year for surgery or other invasive methods of…  
  • FDA Cancer Approvals for Aug 2014 to July 2015
     
  • Investments in cancer care generated $598 billion of additional value for cancer patients diagnosed between 1983 and 1999.  
  • The use of imatinib (Gleevec) has increased the eight-year survival rate for early chronic-phase myelogenous leukemia from 65% to 84%.